Form 4 for TXG 10x Genomics, Inc.
Accepted 2021-12-30 00:00:00 ET · period of report 2021-12-28 · accession 0001567619-21-022725 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2021-12-30 | 2021-12-13 | TXG | Saxonov Serge | CEO, Dir | G - Gift | $0.00 | -360 | 4,138 | -8% | $0 |
| D | 2021-12-30 | 2021-12-28 | TXG | Saxonov Serge | CEO, Dir | M - OptEx | $1.20 | +56.4K | 934.2K | +6% | +$67.6K |
| D | 2021-12-30 | 2021-12-28 | TXG | Saxonov Serge | CEO, Dir | M - OptEx | $0.00 | -56.4K | 52.5K | -52% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2021-12-13 | G | D | 360 | $0.00 | 4,138 | I | — | — | |
| 2 | Common | Class A Common Stock | 2021-12-28 | M | A | 56,363 | $1.20 | 934,218 | D See footnote | — | — | (F1) The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. |
| 3 | Derivative | Stock Option (right to buy) | 2021-12-28 | M | D | 56,363 | $0.00 | 52,535 | D | $1.20 · — to 2027-10-18 | 56,363 Class A Common Stock | (F3) This option, originally for 300,000 shares, of which 247,465 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |